Drug treatment of COVID-19 infection
G Lui, G Guaraldi - Current Opinion in Pulmonary Medicine, 2023 - journals.lww.com
Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …
Molnupiravir: A versatile prodrug against SARS-CoV-2 variants
The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …
[PDF][PDF] Efficacy of Molnupiravir for the treatment of mild or moderate COVID-19 in adults: a meta-analysis
The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …
[HTML][HTML] Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
YC Chang, YC Chen, CC Huang, CM Fu, YT Lee… - International Journal of …, 2023 - Elsevier
Background Molnupiravir is an essential oral antiviral agent against coronavirus disease
2019 (COVID-19); however, its real-world effectiveness has not been evaluated in patients …
2019 (COVID-19); however, its real-world effectiveness has not been evaluated in patients …
Real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 in adult patients during the dominance of the omicron variant: A meta …
C Huang, TL Lu, L Lin - Antibiotics, 2023 - mdpi.com
Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
M Kimata, A Watanabe, Y Yanagida… - Infectious diseases and …, 2023 - Springer
Introduction Molnupiravir is an oral antiviral drug that received special approval for
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
emergency use in Japan on December 24 2021 for infectious disease caused by severe …
HIV and COVID-19 Co-Infection: Epidemiology, Clinical Characteristics, and Treatment
D Basoulis, E Mastrogianni, PM Voutsinas… - Viruses, 2023 - mdpi.com
The COVID-19 pandemic has been a global medical emergency with a significant socio-
economic impact. People with HIV (PWH), due to the underlying immunosuppression and …
economic impact. People with HIV (PWH), due to the underlying immunosuppression and …
[PDF][PDF] Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19
T Feldt, W Guggemos, K Heim, C Lübbert… - Ständiger Arbeitskr der …, 2021 - rki.de
Die SARS-CoV-2-Pandemie stellte unser gesamtes Gesundheitssystem vor große
Herausforderungen. Beispiellos im Zuge der Pandemie wird Evidenz in Studien generiert …
Herausforderungen. Beispiellos im Zuge der Pandemie wird Evidenz in Studien generiert …
Antiviral medications for mild-to-moderate COVID-19 in Japan: a gap of timing between clinical trials and real-world scenarios in a fast-changing pandemic
S Hamaguchi, A Watanabe, Y Nakamoto… - Annals of Clinical …, 2023 - jstage.jst.go.jp
The rapid spread of a novel type of coronavirus infection, coronavirus disease 2019 (COVID-
19) has made it difficult to implement the results of clinical trials in real-world situations. After …
19) has made it difficult to implement the results of clinical trials in real-world situations. After …
Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a …
T Sakaguchi, A Mitsuke, Y Osako, Y Yamada… - BMC nephrology, 2024 - Springer
Abstract Background Kidney transplant recipients (KTRs) are at risk of severe coronavirus
disease 2019 (COVID-19), and even now that Omicron subvariants have become dominant …
disease 2019 (COVID-19), and even now that Omicron subvariants have become dominant …